Chimerix rising: CEO talks IPO success, Phase III strategy
This article was originally published in Scrip
Executive Summary
Chimerix did something that many biotechnology companies aspire to these days: The antiviral drug developer announced plans for an initial public offering in March, completed its $116.9 million IPO little more than a month later, and has kept its stock above the IPO price in the month since.